Literature DB >> 2984237

The vasopressin-sensitive adenylate cyclase in collecting tubules and in thick ascending limb of Henle's loop of human and canine kidney.

B T Ruggles, N Murayama, J L Werness, S M Gapstur, M D Bentley, T P Dousa.   

Abstract

The major tubular effects of [8-Arg]vasopressin (AVP) in regulation of renal water excretion are initiated by stimulation of adenylate cyclase (AdC) coupled with V2 receptors. We explored whether the AVP-sensitive AdC is present in both collecting tubules and the thick ascending limb of Henle's loop of human and canine kidney. In cortical collecting tubule (CCT) and medullary collecting tubules (MCT) of human kidney, AdC was markedly stimulated by AVP [maximum change from basal level (delta), +2700%] and the the nonhormonal stimulatory agent forskolin (delta, +2000%). In human CCT, the effects of both compounds were synergistic. In contrast, AVP had no effect on AdC in either the medullary (MAL) or cortical (CAL) segment of the thick ascending limb of Henle's loop of human kidney; AVP also did not stimulate AdC in CAL or MAL in the presence of forskolin. Similar to that in the human kidney, in the canine kidney, AdC in CCT and MCT was markedly stimulated by AVP and forskolin (delta, +1000%), but AVP had no effect on AdC in CAL and MAL of the canine kidney. In intact tubules dissected from dog kidney and incubated in vitro, AVP markedly increased cAMP accumulation in MCT. AVP also elicited a small but detectable increase in cAMP accumulation in MAL. From these observations, we conclude that AVP-sensitive AdC is well developed in collecting tubules, but that AVP-sensitive AdC is absent in MAL and CAL of human kidney. Likewise, in canine nephron, the AVP-sensitive AdC of MAL and CAL is rudimentary or very labile. These findings suggest that the unresponsiveness of the AdC-cAMP system to AVP in segments of the thick ascending limb of Henle's loop may be a factor that accounts for a relatively low maximum osmotic concentration of urine which can be achieved by human or canine kidneys.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2984237     DOI: 10.1210/jcem-60-5-914

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

Review 1.  AVP dynamically increases paracellular Na+ permeability and transcellular NaCl transport in the medullary thick ascending limb of Henle's loop.

Authors:  Nina Himmerkus; Allein Plain; Rita D Marques; Svenja R Sonntag; Alexander Paliege; Jens Leipziger; Markus Bleich
Journal:  Pflugers Arch       Date:  2016-12-06       Impact factor: 3.657

2.  Antinatriuretic effect of vasopressin in humans is amiloride sensitive, thus ENaC dependent.

Authors:  Anne Blanchard; Michael Frank; Grégoire Wuerzner; Severine Peyrard; Lise Bankir; Xavier Jeunemaitre; Michel Azizi
Journal:  Clin J Am Soc Nephrol       Date:  2011-01-13       Impact factor: 8.237

3.  Characterization of an in vitro system of human renal papillary collecting duct cells.

Authors:  A L Trifillis; M W Kahng
Journal:  In Vitro Cell Dev Biol       Date:  1990-05

Review 4.  Phylogenetic, ontogenetic, and pathological aspects of the urine-concentrating mechanism.

Authors:  Yoshiaki Kondo; Tetsuji Morimoto; Toshiyuki Nishio; Ulviyya Fizuli Aslanova; Minako Nishino; Elnur Ilham Farajov; Noriko Sugawara; Naonori Kumagai; Atsushi Ohsaga; Yoshio Maruyama; Shori Takahashi
Journal:  Clin Exp Nephrol       Date:  2006-09       Impact factor: 2.801

5.  Different localization and regulation of two types of vasopressin receptor messenger RNA in microdissected rat nephron segments using reverse transcription polymerase chain reaction.

Authors:  Y Terada; K Tomita; H Nonoguchi; T Yang; F Marumo
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

6.  Evidence for beta adrenoceptors in proximal tubules. Isoproterenol-sensitive adenylate cyclase in pars recta of canine nephron.

Authors:  N Murayama; B T Ruggles; S M Gapstur; J L Werness; T P Dousa
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.